NCT01952132View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Schizophrenia
Interventions
DRUG

OMS643762

DRUG

Placebo

Trial Locations (1)

90806

Long Beach

Sponsors

Lead Sponsor

Omeros Corporation
All Listed Sponsors
lead

Omeros Corporation

INDUSTRY